(i) Research reveals Philogen’s proprietary immunocytokines are powerful remedy for brain tumors.
(ii) Early promising findings from Philogen’s Section I/II review investigating the safety and efficacy of L19TNF monotherapy in patients with glioblastoma.
(iii) Philogen’s proprietary cancer remedy observed to be protected and perfectly-tolerated.
up to date: Oct 8, 2020 08:00 CEST
October 8, 2020(Newswire.com) –
Philogen S.p.A., a scientific-stage biotechnology corporation targeted on antibody-based therapeutics, is delighted to announce the publication of a peer-reviewed scientific posting in Science Translational Medication. The posting is entitled: “Immunocytokines are a promising immunotherapeutic strategy towards glioblastoma” (T. Weiss, E. Puca, M. Silginer, T. Hemmerle, S. Pazahr, A. Bink, M. Weller, D. Neri, P. Roth, Immunocytokines are a promising immunotherapeutic strategy towards glioblastoma. Sci. Transl. Med. 12, eabb2311 (2020)) and can be accessed below.
The findings of the review display how Philogen’s proprietary antibody-cytokine fusions, referred to as immunocytokines, demonstrated placing one-agent anti-cancer exercise in immunocompetent preclinical versions bearing orthotopic glioblastoma. Moreover, the remedy induced extended-phrase tumor eradications in a proportion of the dealt with animals. These findings ended up of distinct relevance as preclinical versions with glioblastoma simply cannot be fixed by any present conventional of care.
The posting also discusses preliminary scientific success of the initially patients recruited in the PH-L19TNFGLIO-02/eighteen Section I/II trial. Early findings showed that Philogen’s proprietary remedy, onkekafusp alpha (L19TNF), when utilized as a monotherapy induced not only a selective tumor necrosis in all patients (evidenced by distinction-improved and perfusion Magnetic Resonance Imaging), but also furnished situations of prolonged ailment stabilization. Through the review, the remedy was revealed to be protected and perfectly tolerated.
The ongoing Section I/II scientific review (PH-L19TNFGLIO-02/eighteen, https://clinicaltrials.gov/ct2/display/NCT03779230) is investigating the use of L19TNF as a one-agent for the remedy of high-grade glioma at initially recurrence/relapse, a client population with an otherwise incredibly weak prognosis. TNF is sent to cancer lesions by the L19 antibody particular to the EDB area of Fibronectin, a marker for angiogenesis that is expressed in just about all patients with malignant glioma. The Business has formerly demonstrated by nuclear medication processes in extra than 50 patients, that the L19 antibody could efficiently localize in key and secondary brain tumors.
The stage I/II review is open label, in topics with glioblastoma at initially recurrence/relapse and will be executed in two areas: (i) a dose finding aspect to decide the suggested dose of L19TNF (the data of this aspect of the review are printed in the paper), (ii) followed by a sign seeking aspect that investigates initially signs of exercise.
“We are incredibly fired up about the great preclinical success acquired in collaboration with Philogen, which is a leader in the field of focused shipping and delivery of cytokine therapeutics. The emerging scientific success of the ongoing review with L19TNF in glioblastoma – the most malignant brain tumor – gives hope for an option therapeutic possibility for patients struggling from this awful ailment. In a next move, we intention at being familiar with the potential of L19TNF by investigating the merchandise in larger randomised trials.” commented Prof. Michael Weller, Chairman of the Division of Neurology at the College Medical center in Zurich.
Prof. Dario Neri, Co-Chief Executive Officer of Philogen, added: “Our remedy is demonstrating effectiveness at switching the immunologically chilly glioma microenvironment into a sizzling a person, enabling powerful antitumor immunity. We are delighted with the development becoming built with our immunocytokine and are delighted with the wonderful promise this could provide to patients with malignant brain tumors.”
The scientific review is led by Prof. Michael Weller, Dr. Patrick Roth and Dr. Tobias Weiss at the Division of Neurology of the College of Zurich. Philogen functions as the sponsor of the trial.
Philogen is a Swiss-Italian scientific-stage corporation engaged in the discovery and development of novel pharmaceutical and biopharmaceutical goods. Philogen’s approach is to deliver bioactive agents, for case in point cytokines or medicines, to the web page of ailment using antibodies and other ligands that specially and efficiently target stromal antigens. This technologies has created a powerful proprietary pipeline of scientific-stage goods and preclinical compounds in an array of ailment indications. Philogen is headquartered in Siena, Italy, and has research things to do at its subsidiary corporation Philochem in Zürich, Switzerland. Philogen is independently owned, and has signed agreements with numerous big pharmaceutical corporations. For extra details remember to stop by www.philogen.com and www.philochem.com.
For extra details remember to get in touch with:
Dr. Christian Lizak
+forty one () forty three 544 88 00
Consilium Strategic Communications
Mary-Jane Elliott, Melissa Gardiner
Resource: Philogen S.p.A.